New study explores Evolocumab's impact on inflammation in diabetic heart patients
NCT ID NCT03829046
First seen May 01, 2026 · Last updated Jun 12, 2026 · Updated 10 times
Summary
This study looked at how evolocumab (Repatha) affects markers of inflammation and blood vessel health in people with type 2 diabetes and heart disease. 41 participants received either evolocumab or a placebo every 4 weeks for 3 doses. The goal was to understand how this drug might reduce inflammation and improve outcomes, but it was an early-stage exploration, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROVASCULAR DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
St. Michael's - University of Toronto
Toronto, Ontario, M5B1W8, Canada
Conditions
Explore the condition pages connected to this study.